Abstract
The PI3K pathway constitutes an important pathway for regulating the signaling of multiple essential biological processes for which deregulation might contribute to cancer. As such, the PI3K pathway is one of the most frequently altered pathways in human tumors, providing constitutive pathway activation. The evidence indicates that the PI3K pathway is a potential target for cancer chemotherapy. Indeed, many companies and academic laboratories have initiated a variety of approaches to inhibit the pathway at different points. These proteins are kinases, which are very “druggable” targets a priori and, according to the “addiction hypothesis,” cancer cells with this pathway activated will be more dependent upon this pathway for their survival. In this work, we will focus on PI3K protein as a major target for therapeutic intervention. We thoroughly review the clinical achievements and major concerns raised by the pharmacological intervention of PI3Ks.
Keywords: PI3K pathway, inhibitors, cancer, clinical trials, anticancer therapeutic
Current Molecular Pharmacology
Title: Between Bench and Bed Side: PI3K Inhibitors
Volume: 3
Author(s): Luis Paz-Ares and Amancio Carnero
Affiliation:
Keywords: PI3K pathway, inhibitors, cancer, clinical trials, anticancer therapeutic
Abstract: The PI3K pathway constitutes an important pathway for regulating the signaling of multiple essential biological processes for which deregulation might contribute to cancer. As such, the PI3K pathway is one of the most frequently altered pathways in human tumors, providing constitutive pathway activation. The evidence indicates that the PI3K pathway is a potential target for cancer chemotherapy. Indeed, many companies and academic laboratories have initiated a variety of approaches to inhibit the pathway at different points. These proteins are kinases, which are very “druggable” targets a priori and, according to the “addiction hypothesis,” cancer cells with this pathway activated will be more dependent upon this pathway for their survival. In this work, we will focus on PI3K protein as a major target for therapeutic intervention. We thoroughly review the clinical achievements and major concerns raised by the pharmacological intervention of PI3Ks.
Export Options
About this article
Cite this article as:
Paz-Ares Luis and Carnero Amancio, Between Bench and Bed Side: PI3K Inhibitors, Current Molecular Pharmacology 2010; 3 (2) . https://dx.doi.org/10.2174/1874467211003020079
DOI https://dx.doi.org/10.2174/1874467211003020079 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews Expression and Functions of Heat Shock Proteins in the Normal and Pathological Mammalian Eye
Current Molecular Medicine Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Gene Therapy Approaches to Ataxias
Current Gene Therapy The Oxido-reductase Activity of the Apoptosis Inducing Factor: A Promising Pharmacological Tool?
Current Pharmaceutical Design Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Inverse Regulation of MMP-9 and MMP-2 in Long-Term Follow-up After Acute Coronary Syndrome: Lack of Correlation with Platelet and Endothelial Cell Activation Markers
Vascular Disease Prevention (Discontinued) Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology Thienopyridines in Percutaneous Coronary Interventions: Standard Procedures and High Risk Subsets
Current Pharmaceutical Design Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
Inflammation & Allergy - Drug Targets (Discontinued) Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Use of Peripheral Blood Stem Cells in Tissue Engineering
Current Tissue Engineering (Discontinued)